President Trump announced new Most-Favored Nation (MFN) agreements with Eli Lilly and Novo Nordisk, including steps to make their GLP-1 products more affordable across all markets. Additional details follow. New to the MFN agreements are the agreed upon terms for the companies’ GLP-1 products: Lilly’s Zepound and Orforglipron, if approved, and Novo Nordisk’s Ozempic and Wegovy. This includes the following:… (Slifer, November 6, 2025) #Drug Pricing, #Medicare Part D, #Prescription Drugs, #Public Health